<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672006</url>
  </required_header>
  <id_info>
    <org_study_id>MCWisconsin</org_study_id>
    <nct_id>NCT03672006</nct_id>
  </id_info>
  <brief_title>t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection</brief_title>
  <acronym>TOPCAT</acronym>
  <official_title>Tissue Plasminogen Activator Dwells to Reduce Catheter-associated Thrombosis and Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to test feasibility of concept, consent and enrollment&#xD;
      rates, and mechanics of study designed to assess if intra-catheter dwells of tissue&#xD;
      plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed&#xD;
      central line associated blood stream infection (CLABSI) or venous thromboembolism (VTE) in&#xD;
      central venous catheters (CVC) compared to standard of care heparin dwell.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study Children's Hospital of Wisconsin will be a prospective, blinded, randomized&#xD;
      controlled trial enrolling 20 patients in the pediatric intensive care unit (PICU) with a&#xD;
      newly placed central venous catheter (CVC) to receive t-PA or heparin (current standard of&#xD;
      care and defined as placebo for this study) to dwell for a minimum of 30 minutes every three&#xD;
      days until catheter removal or discharge from the PICU. Primary outcomes would be central&#xD;
      line associated blood stream infection (CLABSI) or venous thromboembolism (VTE). Secondary&#xD;
      outcomes would be episodes of CVC dysfunction, off study use of t-PA, and bleeding.&#xD;
&#xD;
      Any patient admitted to the PICU and meeting the inclusion criteria will be approached for&#xD;
      consent within 72 hours CVC placement. Randomization and administration of study drug/placebo&#xD;
      treatment will be initiated within 24 hours of enrollment.&#xD;
&#xD;
      After randomization, study drug/heparin will be infused in the CVC for a dwell duration of 30&#xD;
      minutes-4 hours and then withdrawn (lock therapy) every 3 days until discharge from the PICU,&#xD;
      CVC removal or a maximum of 10 doses received. Additional lumens will be treated on&#xD;
      subsequent days. Any lumen requiring continuous infusion of vaso-active medication will not&#xD;
      receive dwell therapy, evaluated on a day-to-day basis. Timing of instillation of study dwell&#xD;
      medication will be adjusted so as not to interfere with medications for patient care.&#xD;
&#xD;
      This single center, pilot study will enroll 20 subjects.&#xD;
&#xD;
      Procedures to be completed for this study are as follows:&#xD;
&#xD;
      After informed consent/assent, the patient will be randomized and assigned to either the&#xD;
      treatment arm (t-PA lock) or placebo arm (heparin lock). Randomization will be stratified by&#xD;
      age (&lt;5 or ≥5 years old). To maintain the blind, randomization will be done in the&#xD;
      investigational pharmacy prior to the dispensing of the study drug/heparin.&#xD;
&#xD;
      Study Treatment and Dosing In subjects randomized to the t-PA, dosing and administration will&#xD;
      comply with the Children's Hospital and Health System (CHHS) Policy and Procedure Protocol&#xD;
      t-PA Administration for Central Venous Access Devices (CVAD); subjects randomized to the&#xD;
      standard of care heparin group will receive an equivalent volume for weight of heparin&#xD;
      10U/ml. The CVC should be flushed with normal saline prior to infusion of study drug/placebo.&#xD;
      After dwelling time of 30 minutes-4 hours, study drug/placebo should be withdrawn, check for&#xD;
      blood return in CVC and flush line with normal saline as per policy. Each lumen of&#xD;
      multi-lumen CVC should be treated every 3 days until patient discharge from PICU, removal of&#xD;
      CVC, or a maximum of 10 doses of study drug/placebo are received.&#xD;
&#xD;
      Patient weight Volume Study drug/Placebo 0-10kg 0.5ml 10-20kg 1 ml &gt;20kg 2 ml&#xD;
&#xD;
      These doses by body weight have been approved by the FDA for and CHHS Patient Care Protocol&#xD;
      (tPA Administration for Central Venous Access Devices (CVADs) for use in children with CVC&#xD;
      and are not associated with significant bleeding. If a 2mg (ml) dose of t-PA is administered&#xD;
      by bolus injection directly into the systemic circulation, rather than as a dwell within the&#xD;
      CVC, the drug concentration would return to endogenous levels with 30 minutes.&#xD;
&#xD;
      Ultrasound imaging At the end of the study period, a noninvasive ultrasound with doppler will&#xD;
      be performed to assess for asymptomatic thrombosis in the blood vessel of the CVC location.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Centralized pharmacy will prepare and blind the study drug (t-PA) and the control (heparin)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Catheter-associated Venous Thrombosis</measure>
    <time_frame>30 days or ICU discharge</time_frame>
    <description>Catheter-associated Venous Thrombosis upon ICU discharge or 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Catheter-associated Bloodstream Infection</measure>
    <time_frame>30 days or ICU discharge</time_frame>
    <description>CLABSI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Episodes of CVC Dysfunction</measure>
    <time_frame>30 days or ICU discharge</time_frame>
    <description>Episodes of CVC dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Off Study Use of t-PA</measure>
    <time_frame>30 days or ICU discharge</time_frame>
    <description>off study use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Bleeding</measure>
    <time_frame>30 days or ICU discharge</time_frame>
    <description>clinically significant bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Central Venous Catheter Thrombosis</condition>
  <condition>Central Venous Catheter Associated Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alteplase (recombinant t-PA)</intervention_name>
    <description>Medication administered to dwell in central venous catheter</description>
    <arm_group_label>alteplase</arm_group_label>
    <other_name>tpa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Medication administered to dwell in central venous catheter</description>
    <arm_group_label>Heparin</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0 - ≤ 18 years old&#xD;
&#xD;
          -  PICU admission&#xD;
&#xD;
          -  CVC placed within 72 hours of enrollment (tunneled such as peripherally inserted&#xD;
             central catheter (PICC), Broviac or Hickman, or untunneled) and in place during&#xD;
             hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Non-English-speaking subjects and/or parent/guardian&#xD;
&#xD;
          -  Platelet count &lt; 20,000&#xD;
&#xD;
          -  Active CVC infection-defined as positive blood culture from the in -situ CVC at time&#xD;
             of enrollment&#xD;
&#xD;
          -  Current radiographically confirmed VTE&#xD;
&#xD;
          -  Currently receiving treatment doses of anticoagulation (heparin infusion &gt;15U/kg/hr,&#xD;
             enoxaparin injections &gt;=2mg/kg/day or &gt;=60mg/day)&#xD;
&#xD;
          -  CVC diameter &lt;1.9 Fr&#xD;
&#xD;
          -  Current or previous diagnosis of Heparin Induced Thrombocytopenia or allergy to&#xD;
             heparin or t-PA&#xD;
&#xD;
          -  Med-a-port catheters&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Sheila Hanson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Upper Extremity Deep Vein Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03672006/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03672006/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alteplase</title>
          <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
        </group>
        <group group_id="P2">
          <title>Heparin</title>
          <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>exclusion criteria met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alteplase</title>
          <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
        </group>
        <group group_id="B2">
          <title>Heparin</title>
          <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="1.1" upper_limit="11"/>
                    <measurement group_id="B2" value="3" lower_limit="1.25" upper_limit="11"/>
                    <measurement group_id="B3" value="3" lower_limit="2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CVC type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Untunneled</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PICC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Broviac/Hickman</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Catheter-associated Venous Thrombosis</title>
        <description>Catheter-associated Venous Thrombosis upon ICU discharge or 30 days</description>
        <time_frame>30 days or ICU discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
          </group>
          <group group_id="O2">
            <title>Heparin</title>
            <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Catheter-associated Venous Thrombosis</title>
          <description>Catheter-associated Venous Thrombosis upon ICU discharge or 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Catheter-associated Bloodstream Infection</title>
        <description>CLABSI</description>
        <time_frame>30 days or ICU discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
          </group>
          <group group_id="O2">
            <title>Heparin</title>
            <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Catheter-associated Bloodstream Infection</title>
          <description>CLABSI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of CVC Dysfunction</title>
        <description>Episodes of CVC dysfunction</description>
        <time_frame>30 days or ICU discharge</time_frame>
        <population>episode of CVC dysfunction as inability to flush or draw</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
          </group>
          <group group_id="O2">
            <title>Heparin</title>
            <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of CVC Dysfunction</title>
          <description>Episodes of CVC dysfunction</description>
          <population>episode of CVC dysfunction as inability to flush or draw</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Off Study Use of t-PA</title>
        <description>off study use</description>
        <time_frame>30 days or ICU discharge</time_frame>
        <population>number of episodes of off-study t-PA use</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
          </group>
          <group group_id="O2">
            <title>Heparin</title>
            <description>patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Off Study Use of t-PA</title>
          <description>off study use</description>
          <population>number of episodes of off-study t-PA use</population>
          <units>doses</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Bleeding</title>
        <description>clinically significant bleeding</description>
        <time_frame>30 days or ICU discharge</time_frame>
        <population>Bleeding events defined as clinically significant</population>
        <group_list>
          <group group_id="O1">
            <title>Alteplase</title>
            <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
          </group>
          <group group_id="O2">
            <title>Heparin</title>
            <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Bleeding</title>
          <description>clinically significant bleeding</description>
          <population>Bleeding events defined as clinically significant</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after study completion</time_frame>
      <desc>clinical bleeding</desc>
      <group_list>
        <group group_id="E1">
          <title>Alteplase</title>
          <description>10 patients received 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)&#xD;
alteplase (recombinant t-PA): Medication administered to dwell in central venous catheter</description>
        </group>
        <group group_id="E2">
          <title>Heparin</title>
          <description>9 patients received 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)&#xD;
Heparin: Medication administered to dwell in central venous catheter</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shelia Hanson</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-266-3728</phone>
      <email>shanson@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

